I failed 3lines of TKIs,I can try thisagent nextDrug classthatrevolutionizedCMLtreatmentI have theT315I mutationbut also haveelevated lipaseThis TKI hasthe mostmetabolicsyndromeToo many ofthese bloodcells areabnormal inCMLThelandmarkfor thefirst TKIAfter 3months, I have3% BCR-ABL,I have this TKIresponseTreatmentfor blastphaseCMLTranslocationbetweenthese twochromosomesoccur in CMLResponsewhen BCR-ABL1 (IS)is <0.01%The current5-yearoverallsurvival rateof CMLI want toavoid thisTKI if I donot wantdiarrheaThe scoringsystem usedin chronicphaseModerateto highemetogenicrisk TKIsPercentageof blastspresent inthe blastphase60-70% ofpatients withCML presentwith thissymptomThe numberof distinctclinicalphases inCMLTKIs aremajorsubstratesfor this liverenzymeWhen togive H2RAswithdasatinibPatients havepresence of thisBCR-ABLproteinindicative ofCML Therecommendedcriteria usedfor acceleratedphaseNon-pharmacologicaltreatment forCMLNumber ofblastspresent inacceleratedphaseI avoid thisdrug classwith bosutinib,nilotinib anddasatinibI failed 3lines of TKIs,I can try thisagent nextDrug classthatrevolutionizedCMLtreatmentI have theT315I mutationbut also haveelevated lipaseThis TKI hasthe mostmetabolicsyndromeToo many ofthese bloodcells areabnormal inCMLThelandmarkfor thefirst TKIAfter 3months, I have3% BCR-ABL,I have this TKIresponseTreatmentfor blastphaseCMLTranslocationbetweenthese twochromosomesoccur in CMLResponsewhen BCR-ABL1 (IS)is <0.01%The current5-yearoverallsurvival rateof CMLI want toavoid thisTKI if I donot wantdiarrheaThe scoringsystem usedin chronicphaseModerateto highemetogenicrisk TKIsPercentageof blastspresent inthe blastphase60-70% ofpatients withCML presentwith thissymptomThe numberof distinctclinicalphases inCMLTKIs aremajorsubstratesfor this liverenzymeWhen togive H2RAswithdasatinibPatients havepresence of thisBCR-ABLproteinindicative ofCML Therecommendedcriteria usedfor acceleratedphaseNon-pharmacologicaltreatment forCMLNumber ofblastspresent inacceleratedphaseI avoid thisdrug classwith bosutinib,nilotinib anddasatinib

Chronic Myeloid Leukemia BINGO - Call List

(Print) Use this randomly generated list as your call list when playing the game. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
O
2
N
3
N
4
O
5
N
6
G
7
I
8
I
9
G
10
B
11
I
12
B
13
B
14
G
15
B
16
G
17
O
18
I
19
G
20
B
21
N
22
O
23
O
24
I
  1. O-I failed 3 lines of TKIs, I can try this agent next
  2. N-Drug class that revolutionized CML treatment
  3. N-I have the T315I mutation but also have elevated lipase
  4. O-This TKI has the most metabolic syndrome
  5. N-Too many of these blood cells are abnormal in CML
  6. G-The landmark for the first TKI
  7. I-After 3 months, I have 3% BCR-ABL, I have this TKI response
  8. I-Treatment for blast phase CML
  9. G-Translocation between these two chromosomes occur in CML
  10. B-Response when BCR-ABL1 (IS) is <0.01%
  11. I-The current 5-year overall survival rate of CML
  12. B-I want to avoid this TKI if I do not want diarrhea
  13. B-The scoring system used in chronic phase
  14. G-Moderate to high emetogenic risk TKIs
  15. B-Percentage of blasts present in the blast phase
  16. G-60-70% of patients with CML present with this symptom
  17. O-The number of distinct clinical phases in CML
  18. I-TKIs are major substrates for this liver enzyme
  19. G-When to give H2RAs with dasatinib
  20. B-Patients have presence of this BCR-ABL protein indicative of CML
  21. N-The recommended criteria used for accelerated phase
  22. O-Non-pharmacological treatment for CML
  23. O-Number of blasts present in accelerated phase
  24. I-I avoid this drug class with bosutinib, nilotinib and dasatinib